Subjects with CRS (n=49) | Subjects without CRS (n=109) | |||
Characteristics | Never-smokers (n=22) | Smokers (n=27) | Never-smokers (n=69) | Smokers (n=40) |
Age, yr (range) |
55.8 ± 12.9 (40-82) |
59.5 ± 11.2 (40-81) |
57.5 ± 10.8 (40-80) |
57.6 ± 13.3 (41-85) |
Male gender, n (%) | 8 (36.4) | 23 (85.2) | 15 (21.7) | 32 (80.0) |
Smoking index, packxyr | 0 | 25.0 ± 26.6 | 0 | 30.9 ± 25.5 |
Severity of CRS on facial CT† | 13.0 ± 4.4 | 11.5 ± 3.8 | 0.7 ± 0.8 | 1.0 ± 0.8 |
Nasal polyp, yes (%) | 5 (22.7) | 3 (11.1) | 0 (0) | 0 (0) |
FVC, L | 3.1 ± 0.9 | 3.3 ± 0.8 | 2.8 ± 0.6 | 3.6 ± 0.9 |
%FVC predicted, % | 77.0 ± 7.2 | 91.4 ± 16.1 | 79.8 ± 6.1 | 98.0 ±13.8 |
FEV1, L | 3.0 ± 2.8 | 2.3 ± 0.7 | 2.3 ± 0.6 | 2.7 ± 0.8 |
%FEV1 predicted, % | 78.6 ± 7.3 | 75.0 ± 19.2 | 81.0 ± 6.3 | 85.3 ± 18.3 |
FEV1/FVC ratio | 0.77 ± 0.07 | 0.69 ± 0.13 | 0.80 ± 0.06 | 0.74 ± 0.13 |
FEV1/FVC ratio <0.7, n (%) GOLD stage I/II/III/IV‡ |
5 (22.7) 0/5/0/0 |
11 (40.7) 2/6/2/1 |
3 (4.3) 0/3/0/0 |
11 (27.5) 2/8/0/1 |
<LLN, n (%) |
4 (18.2) |
12 (44.4) |
3 (4.3) |
12 (30.0) |
Blood eosinophil counts, /mm3 | 226 ± 21 | 268 ± 20 | 157 ± 10 | 152 ± 14 |
serum total IgE levels, IU/mL | 114 ± 365 | 426 ± 586 | 117 ± 175 | 303 ± 783 |